- Home
- RBOT vs ASBP Comparison
RBOT vs ASBP Comparison
Compare RBOT & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | ASBP |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 18.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | ASBP |
|---|---|---|
| Price | $2.23 | $0.10 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 159.3K | ★ 18.7M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.36 | $0.07 |
| 52 Week High | $18.97 | $15.80 |
Technical Indicators
Market Signals| Indicator | RBOT | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 30.74 | 37.04 |
| Support Level | $2.36 | $0.07 |
| Resistance Level | $2.58 | $0.11 |
| Average True Range (ATR) | 0.32 | 0.01 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 2.78 | 62.30 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.